Imidazotriazinone compounds
US-9725453-B2 · Aug 8, 2017 · US
Substituted imidazo[1,5-a]pyrazines as PDE9 inhibitors
US9993477B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9993477-B2 |
| Application number | US-201715452827-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 8, 2017 |
| Priority date | Oct 10, 2011 |
| Publication date | Jun 12, 2018 |
| Grant date | Jun 12, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for inhibiting phosphodiesterase 9 activity in a subject, comprising administering to the subject a therapeutically effective amount of 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one, or a tautomer or a pharmaceutically acceptable acid addition salt thereof. 2. The method of claim 1 , wherein the subject has a neurodegenerative disorder selected from the group consisting of Alzheimer's disease, mental retardation, cognitive impairment associated with schizophrenia, attention-deficit/hyperactivity disorder, age-related cognitive decline, and substance-induced psychotic disorder. 3. The method of claim 2 , wherein the substance-induced psychotic disorder is psychosis induced by alcohol, psychosis induced by amphetamine, psychosis induced by cannabis , psychosis induced by cocaine, psychosis induced by hallucinogens, psychosis induced by inhalants, psychosis induced by opioids, or psychosis induced by phencyclidine. 4. A method for inhibiting phosphodiesterase 9 activity in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one, or a tautomer or a pharmaceutically acceptable acid addition salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients. 5. The method of claim 4 , wherein the subject has a neurodegenerative disorder selected from the group consisting of Alzheimer's disease, mental retardation, cognitive impairment associated with schizophrenia, attention-deficit/hyperactivity disorder, age-related cognitive decline, and substance-induced psychotic disorder. 6. The method of claim 5 , wherein the substance-induced psychotic disorder is psychosis induced by alcohol, psychosis induced by amphetamine, psychosis induced by cannabis , psychosis induced by cocaine, psychosis induced by hallucinogens, psychosis induced by inhalants, psychosis induced by opioids, or psychosis induced by phencyclidine.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for treating abnormal movements, e.g. chorea, dyskinesia · CPC title
for treating abuse or dependence · CPC title
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9993477B2 cover?
- This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) The present invention fur…
- Who is the assignee on this patent?
- H Lundbeck As
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).